tirzepatide week 4 weight loss percent Medscape | Retatrutide, Eli Lilly's first-in-class triple hormone receptor agonist, delivered meaningful at 80 weeks in all doses in the How much have you lost

10.1016/j.jagp.2023.08.010 13 ChenJ.HsuT.LiuJ.PanH.LaiC.YangS.et al (2025)

At 72 weeks, tirzepatide produced an average weight reduction of about 20%, compared to roughly 14% with semaglutide

A team of researchers at the University of Bern, Switzerland, recently reported that the use of the antidiabetic medicine semaglutide is associated with an increased risk of vision impairment

That is a real program wrapped around the prescription, not a token add-on

Other At-Risk Groups GLP-1 medications are generally not suitable for individuals with severe gastrointestinal disorders like gastroparesis, those with type 1 diabetes (as these drugs are approved only for type 2 diabetes and obesity), and people with a history of suicidal thoughts, active eating disorders, or heavy alcohol use